EBM Bottom Line Summary:
Ticagrelor Without Aspirin After PCI

This Bottom Line Summary reviews findings from the ULTIMATE-DAPT trial, which examined the impact of stopping aspirin one month after percutaneous coronary intervention (PCI) while continuing ticagrelor. The study found that this approach significantly reduced bleeding risk without increasing major cardiovascular events. These results may help inform shared decision-making for patients at risk of bleeding.